hexamethonium has been researched along with Benign Neoplasms, Brain in 2 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| GUIDETTI, B | 1 |
| ALVISI, C | 1 |
| Nelson, ME | 1 |
| Lindstrom, J | 1 |
2 other studies available for hexamethonium and Benign Neoplasms, Brain
| Article | Year |
|---|---|
[Hexamethonium in neurosurgery and neurology].
Topics: Analgesia; Anesthesia; Anesthesia and Analgesia; Brain; Brain Neoplasms; Hexamethonium; Hypotension; | 1954 |
Single channel properties of human alpha3 AChRs: impact of beta2, beta4 and alpha5 subunits.
Topics: Animals; Brain Neoplasms; Electrophysiology; Hexamethonium; Humans; Kinetics; Mecamylamine; Neurobla | 1999 |